What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Portfolio Pulse from Vandana Singh
Astellas Pharma has decided not to exercise its option to obtain an exclusive license to TSHA-120 under the Option Agreement with Taysha Gene Therapies. This decision comes after Taysha submitted a new comprehensive analysis to the FDA in June 2023, with the FDA recommending a randomized, double-blind, placebo-controlled trial as the optimal path to demonstrate efficacy in TSHA-120. Following this, Taysha's shares fell by 6.13%.
September 20, 2023 | 6:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Astellas Pharma's decision not to license TSHA-120 may indicate a lack of confidence in the drug's potential, which could impact investor sentiment.
Astellas Pharma's decision not to exercise its option to license TSHA-120 could be interpreted as a lack of confidence in the drug's potential. This could impact investor sentiment and potentially the company's stock price, although the direct impact may be limited as it is one of many drugs in Astellas' portfolio.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Taysha Gene Therapies' stock price fell by 6.13% following Astellas Pharma's decision not to license TSHA-120 and the FDA's recommendation for a more rigorous trial.
Taysha's stock price fell by 6.13% following the news, indicating a negative impact on investor sentiment. The FDA's recommendation for a more rigorous trial could also delay potential revenue from TSHA-120, further impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100